Uniqure NV
QURE
查看详细走势图
14.770USD
0.0000.00%
收盘 03/27, 16:00（美东）报价延迟15分钟
248.06M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
0.00%
5天
-8.20%
1月
-5.50%
6月
-75.13%
今年开始到现在
-38.28%
1年
+18.44%
查看详细走势图
TradingKey Uniqure NV股票评分
单位: USD 更新时间: 2026-03-27操作建议
Uniqure NV当前公司基本面数据相对稳定，最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名63/391位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价37.08。中期看，股价处于下降通道。近一个月，市场表现很强，技术面评分较高，但很强的走势得没有得到基本面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Uniqure NV评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Uniqure NV亮点
亮点风险
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
业绩增长期
公司处于发展阶段，最新年度总收入16.10M美元
估值低估
公司最新PE估值-4.27，处于3年历史低位
机构减仓
最新机构持股59.61M股，环比减少3.63%
保罗·都铎·琼斯持仓
明星投资者保罗·都铎·琼斯持仓，最新持仓市值74.04K
分析师目标
根据
15
位分析师
买入
评级
37.083
目标均价
+137.71%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Uniqure NV新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Uniqure NV简介
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
公司代码QURE
公司Uniqure NV
CEOKapusta (Matthew)
网址https://www.uniqure.com/
相关品种
